The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

An oncology leader views AI's most powerful near-term application as handling tedious logistical and bureaucratic tasks, not discovering novel molecules. By automating paperwork and trial planning, AI can liberate scientists to spend more time on deep, creative thinking that drives breakthroughs.

Martin Shkreli argues that the primary bottleneck in drug development isn't finding new molecules, but the immense inefficiency caused by poor communication, irrational decision-making, and misaligned incentives across numerous human departments. He believes AI's greatest contribution will be optimizing this complex organizational process rather than just improving discovery.

The $5 billion cost to develop a drug is primarily driven by the high failure rate (9 out of 10) in late-stage trials. AI's biggest financial impact will be predicting which drugs will succeed, drastically reducing wasted R&D. This efficiency is what will ultimately make drugs more affordable.

While AI holds long-term promise for molecule discovery, its most significant near-term impact in biotech is operational. The key benefits today are faster clinical trial recruitment and more efficient regulatory submissions. The revolutionary science of AI-driven drug design is still in its earliest stages.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

Many diseases have well-understood genetic causes but lack effective treatments. Genesis CEO Evan Feinberg argues this makes drug discovery the most impactful area for AI, as it directly addresses the bottleneck of creating selective therapies for known targets where no medicine currently exists.

Claims that AI will slash drug development from 12 years to 2 are unrealistic due to the biological necessity of long-term patient monitoring for safety and efficacy. The truly underestimated impact of AI is the massive productivity gain from deploying AI agents to augment every employee across the entire pharma value chain.